drugset / Trial / NCT01901198
Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein single dose in Chinese healthy volunteers.
Timeline
- Start
- 2013-04
- Primary completion
- 2013-09
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Serum Albumin/interferon alpha2a Fusion Protein | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |
Indications
No indication recorded.